Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In an attempt to associate oropharyngeal excretion of Epstein-Barr (EB) virus with lymphoproliferative disorders other than infectious mononucleosis, we tested throat gargles collected from adult subjects for the EB virus. Nine (16%) of 55 healthy persons were positive. High EB virus-excretion rates were found among patients with active acute lymphocytic leukemia (6/6, 100%), among renal homograft recipients during the third to 12th month after transplantation (26/30, 87%), and among critically ill patients with leukemia-lymphoma (14/19, 74%). Moderately high excretion rates were found among patients with myeloma (7/16, 44%), patients with poorly differentiated lymphocytic lymphoma (5/11, 44%), critically ill patients with solid cancers (15/37, 41%), and patients with chronic myelogenous leukemia (8/21, 38%). Our data suggested that the higher than normal excretion rate is realted to the basic disease process and to the general health status but not to the duration of cancer chemotherapy.
 ...
PMID:Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. 20 83

Two hundred and eight acceptable patients were treated with Yoshi 864 (2 mg/kg/day by iv push X 5 days repeated once every 6 weeks). Toxicity was minimal. There was an overall response rate of 11%. Cross resistance with other alkylating agents may not be present. Because of its lack of toxicity, Yoshi 864 should be further evaluated in chronic myelocytic leukemia, lymphomas, and carcinomas of the ovary and bladder where significant responses were seen. It should also be evaluated in combinations as a replacement for other alkylating agents which cause more nausea and vomiting.
Cancer Treat Rep 1978 Mar
PMID:Yoshi 864 (1-propanol, 3,3'-iminodi-, dimethanesulfonate [ester], hydrochloride): a phase II study in solid tumors. 20 59

Cancer chemotherapy was purely palliative until the early sixties. Tumor cures have been since obtained, first in malignant trophoblastoma and Burkitt's lymphoma, and more recently in Hodgkin's disease, diffuse histiocytic lymphoma, acute lymphocytic leukemia in children, Wilms's tumor and osteosarcoma. Preliminary data are suggestive of tumor cures in testicular teratomas and, possibly, in small cell carcinoma of the lung. Five patients with trophoblastoma, Hodgkin's disease, melanoma, chronic myelocytic leukemia and anaplastic carcinoma of the lung are briefly presented, all without evidence of tumor relapse 3 years or more after chemotherapy. Theoretical bases for improvement of the curative effect of cancer chemotherapy are discussed, including the development of new agents, and new pharmacological problems concerning drug interactions, complexes of drugs with macromolecules or immunoglobulins and liposomes are considered.
 ...
PMID:[Curability of malignant neoplasms: value and limitations of chemotherapy]. 21 68

The phagocytosis (in the absence of serum factors) of zymosan particles by peripheral leukocytes isolated from ten patients with acute leukemia (AMbL, AMoL, AMML, AUL, ALL and CML-BC) was studied at the electron microscope. An evident phagocytic activity was observed only in the cells in which cytochemical and ultrastructural features suggested that the blast elements belonged to the monocytic series. However, no phagocytosis by unclassifiable leukemic blasts was observed, even though they had some submicroscopic characteristics of the monocytic series. These findings suggest that phagocytic capacity develops during the course of cell differentiation, becoming striking only when the blast cell acquires the ultrastructural features of the pro-monocytic stage. Using the myeloperoxidase reaction, this study also demonstrates a morphological alteration in the degranulation process after the ingestion of zymosan particles in both the blasts and the mature PMN cells of leukemic patients. This defect could be related to the susceptibility to severe infections usually found in subjects with hematological malignancies.
 ...
PMID:Ultrastructural study of leukemic cell phagocytosis using the myeloperoxidase reaction. 22 98

There are both defined and evolving roles for radiation therapy in the management of adult leukemias. For the acute leukemias, emphasis presently is on adjuvant irradiation of local manifestations including CNS "prophylaxis" for subclinical meningeal involvement. In chronic myelocytic leukemia, local palliative radiotherapy is complemented by the use of splenic irradiation for its systemic effect. Recently, total body irradiation has been shown to influence the natural history of chronic lymphocytic leukemia. For the first time, it has been possible to achieve remissions that prolong survival as well as improve the quality of life. Future exploitation or radiotherapy in adults with leukemia will be dependent upon improved communication and cooperation between the various medical specialists concerned with patient care in these diseases.
Cancer 1977 Feb
PMID:Role of radiation therapy in management of adult leukemia. 26 99

The present status of knowledge about the platelet membrane components suggests that glycoproteins (GP) are involved in the intercellular platelet specific reactions, such as adhesion and aggregation. Normal human platelets and platelet membranes solubilized under dissociating conditions produce characteristic polypeptide and GP electrophoretic patterns (PAGE). Platelets and isolated platelet membranes from patients with chronic myeloid leukemia (CML) presented dissimilarities of their glycoconjugates as compared to the normal platelets. The modification of the electrophoretic banding visualized by the periodic acid-Schiff's reagent (PAS) consisted in the decrease of the 155,000 GP L, the presence of two PAS positive bands in the area of the 135,000 normal PAS positive GP LL and a variable decrease of the 100,000 GP LLL (Apparent mol. wt. are indicated). In addition, preliminary data showed an increased catalytic transfer of the labelled galactosyl and N acetygalactosaminyl residues from exogenous nucleotide 14C-sugar precursors onto the CML-platelet endogenous sugar acceptors. These firstly reported data on molecular abnormalities of the platelet membrane GP in CML, suggested their possible relationship with the impaired platelet adhesion and aggregation occurring in this disease or the ability of leukemic platelets to express modified surface membrane components.
Int J Cancer 1977 Feb 15
PMID:[Altered platelet surface glycoproteins in chronic myeloid leukemia (author's transl)]. 26 46

Cytogenetic examination of bone marrow cells from three patients with juvenile chronic granulocytic leukemia (CGL) showed 46,XX,3p-,11p+ ,t(11p:3p) in one case, 45XY,-E in another, and 45X(X),-C/47,XX,+G in the third. The case with the translocated chromosome originally presented like an acute lymphocytic leukemia (ALL). TAn overt clinical picture of juvenile CGL emerged two and a half years later. Serial study of this case revealed no cytogenetic abnormalities until two years after the diagnosis of ALL, when the translocated chromosome was first observed. Unlike the Ph1 chromosome in adult type CGL, chromosomal abnormalities in juvenile CGL lack specificity, resembling ALL in this respect.
Cancer 1977 May
PMID:Cytogenetics of juvenile type chronic granulocytic leukemia. 26 49

Repeated single doses of busulfan (50-200 mg) were given over 1--2 days to 17 patients with chronic myeloid leukemia. The mean survival time was 137 weeks. In this small trial the drug was shown to be safe in most but not all patients and as effective as continous busulfan.
Cancer Treat Rep
PMID:Treatment of chronic myeloid leukemia with repeated single doses of busulfan. 26 18

A case of Ph1-positive chronic myelocytic leukemia associated with a complex translocation involving chromosomes No. 9, No. 17, and No. 22 was described. All cells in the marrow contained this complex karyotypic picture, and no cells with the usual type of Ph1 translocation were present. With banding analysis, the karyotypic picture consisted of 46,XX,t(9;22;17)(q34;q11;q21). The published cases of usual and complex Ph1 translocations were summarized in tabular form and some aspects of the translocations discussed.
J Natl Cancer Inst 1977 Jun
PMID:A new complex Ph1 translocation involving three chromosomes. 26 28

A combination of eight cytotoxic drugs, administered simultaneously, has been used in 86 cases of acute leukemia. The regimen, designated TRAMPCOL, incorporated thioguanine, rubidomycin, (daunorubicin), cytosine arabinoside, methotrexate, prednisolone, cyclophosphamide, vincristine, and usually L-asparaginase. Treatment was administered in five-day pulses with treatment-free intervals varying from nine to 23 days. Subjective and objective toxic effects were not more severe than those seen with two- and four-drug regimens previously employed. Substantial clinical and hematologic improvement occurred in 8/19 patients with chronic granulocytic leukemia (CGL) in acute transformation. Complete clinical and hematologic remission (CR) was achieved in 3/7 patients with untreated acute myeloid leukemia (AML), 5/19 patients with AML who had failed to achieve CR with other therapy, and 4/18 patients with AML in relapse after CR obtained with regimens other than TRAMPCOL. CR occurred in 15/17 patients with acute lymphocytic leukemia (ALL), most of whom had had multiple previous relapses. CR was not achieved in four patients with AML superimposed on pre-existing myeloproliferative disorders. The TRAMPCOL regimen merits further evaluation in CGL after acute transformation, as a primary treatment for AML, and as therapy for ALL 1) in relapse, 2) in adults, 3) in children with adverse prognostic features, and 4) in T-cell ALL.
Cancer 1977 Jul
PMID:Multiple-drug chemotherapy for acute leukemia The TRAMPCOL regimen: results in 86 patients. 26 3


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>